TOX as a potential target for immunotherapy in lymphocytic malignancies

Biomarker Research

Yujie Zhao¹  Shaohua Chen¹  Yangqiu Li¹  Shuxin Huang¹  Chaofeng Liang² 

[1] Key Laboratory for Regenerative Medicine of Ministry of Education; Institute of Hematology, School of Medicine, Jinan University, 510632, Guangzhou, China;Key Laboratory for Regenerative Medicine of Ministry of Education; Institute of Hematology, School of Medicine, Jinan University, 510632, Guangzhou, China;Department of Anatomy and Molecular Embryology, Institute of Anatomy, Ruhr-University Bochum, 44801, Bochum, Germany;

关键词: Thymocyte selection-associated HMG BOX;    Biological function;    T cell exhaustion;    Lymphocytic malignancies;    Immune biomarker;    Immunotherapy;   

DOI  :  10.1186/s40364-021-00275-y

来源: Springer

【 摘 要 】

TOX (thymocyte selection-associated HMG BOX) is a member of a family of transcriptional factors that contain the highly conserved high mobility group box (HMG-box) region. Increasing studies have shown that TOX is involved in maintaining tumors and promoting T cell exhaustion. In this review, we summarized the biological functions of TOX and its contribution as related to lymphocytic malignancies. We also discussed the potential role of TOX as an immune biomarker and target in immunotherapy for hematological malignancies.

【 授权许可】

CC BY